1 HOUR CYP2C19 GENOTYPING

FDA 510(k)-Cleared and CE Marked

Rapid CYP2C19 Genotyping can aid in the implementation of genotype-guided dual antiplatelet therapy (DAPT)1
U.S. AHA/ASA guidelines2 recommend dual antiplatelet therapy (DAPT) within 12-24 hours of first stroke or TIA to prevent recurrent stroke for minor stroke or high-risk TIA. Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines recommend ticagrelor in place of clopidogrel in minor stroke/high-risk TIA patients carrying a CYP2C19 loss of function allele.1
Genomadix Cube

The Genomadix Cube
System Tests for...

The Genomadix Cube System Tests for...

The Genomadix Cube
System Tests for...

The Genomadix Cube System Tests for...

CYP2C19

looking for a customized solution for your organization?
Click Here

APOE

looking for a customized solution for your organization?
Click Here

Legionella

looking for a customized solution for your organization?
Click Here

Looking For A Customized Solution For Your Organization?

GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM

GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM (OTTAWA, March 22, 2023) Genomadix , based in Ottawa,

Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic

Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered

Assets of Spartan Bioscience Inc. To Be Acquired By Casa-Dea Finance Limited

GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Spartan Bioscience Inc. (Spartan) announces today that its primary assets will be acquired

  1. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467 | 2. Pan Y, et al. JAMA Neurol. 2022;79(8):739–745
  1. Lee et al., Clin Pharmacol Ther. 2022 November ; 112(5): 959–967. doi:10.1002/cpt.2526 |
  2. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467.
Scroll to Top